Histiocytic Ulcerative Colitis

Histiocytic ulcerative colitis (HUC) is a rare, chronic, idiopathic inflammatory bowel disease (IBD) of the large intestine, primarily affecting young Boxer dogs, but also reported in other breeds. It is characterized by severe, progressive ulcerative colitis with dense infiltration of the colonic lamina propria by large, periodic acid-Schiff (PAS)-positive macrophages (histiocytes). The condition is also known as 'Boxer colitis' or 'granulomatous colitis of Boxers'. The disease is typically confined to the colon and rectum, causing clinical signs of chronic large-bowel diarrhea, tenesmus, hematochezia, and mucoid feces. Without appropriate treatment, HUC can be debilitating and potentially fatal, but with early diagnosis and targeted antimicrobial therapy, remission is achievable.

The exact etiology of histiocytic ulcerative colitis remains incompletely understood, but current evidence strongly implicates an infectious trigger, specifically Escherichia coli. Studies have identified adherent and invasive E. coli (AIEC) strains within the colonic mucosa of affected dogs, particularly strains expressing the FimH adhesin, which facilitates adherence to and invasion of intestinal epithelial cells. These bacteria are capable of surviving and replicating within macrophages, leading to the characteristic histiocytic infiltration. Genetic predisposition is also considered a major factor, as HUC is overrepresented in Boxer dogs, suggesting an inherited defect in macrophage bacterial killing or an abnormal immune response to enteric bacteria. Other potential etiologies include dysbiosis of the gut microbiome, altered mucosal immunity, and environmental factors, but no single causative agent has been definitively proven. The disease is not considered contagious, and no viral, fungal, or parasitic agents have been consistently identified.

Histiocytic ulcerative colitis is a rare disease, with the highest prevalence in Boxer dogs, accounting for the majority of reported cases. It has also been documented in other breeds, including French Bulldogs, Mastiffs, Alaskan Malamutes, and mixed-breed dogs, but with much lower frequency. The disease typically manifests in young dogs, with most cases diagnosed before 2 years of age, although older dogs can be affected. There is no clear sex predilection, with both males and females equally affected. Geographic distribution appears to be worldwide, with cases reported in North America, Europe, and other regions. The incidence is not well established, but it is considered an uncommon cause of chronic colitis in dogs. Breed-specific genetic risk is evident, particularly in Boxers, where a familial pattern has been suggested, although the mode of inheritance is not clearly defined. No seasonal or environmental factors have been consistently associated with the disease.

The pathophysiology of histiocytic ulcerative colitis involves a complex interplay between bacterial invasion, defective macrophage function, and dysregulated mucosal immunity. The initiating event is believed to be colonization of the colonic mucosa by adherent and invasive E. coli (AIEC). These bacteria adhere to intestinal epithelial cells via FimH adhesins and invade the epithelium, gaining access to the lamina propria. Once in the lamina propria, they are phagocytosed by macrophages. In affected dogs, there is a defect in the intracellular killing of these bacteria, likely due to genetic mutations affecting macrophage function, such as impaired phagolysosomal maturation or reduced production of reactive oxygen species. Consequently, the bacteria survive and replicate within macrophages, leading to the accumulation of large, foamy, PAS-positive macrophages in the lamina propria. These macrophages produce pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), which recruit additional inflammatory cells and cause tissue damage. The chronic inflammatory response results in mucosal ulceration, crypt abscesses, and architectural distortion of the colonic mucosa. The ulceration leads to clinical signs of hematochezia and mucoid diarrhea. The inflammatory process is typically confined to the colon and rectum, with the small intestine usually spared. Over time, chronic inflammation can lead to fibrosis and stricture formation, although this is uncommon. The systemic effects are generally limited, but severe cases may result in protein-losing enteropathy and weight loss.

The primary predisposing factor for histiocytic ulcerative colitis is breed, with Boxer dogs being at significantly higher risk, suggesting a genetic predisposition. A familial association has been observed, indicating a possible inherited defect in immune function. Age is another factor, as the disease predominantly affects young dogs under 2 years of age. Other potential predisposing factors include alterations in the gut microbiome, such as dysbiosis, which may allow pathogenic E. coli to proliferate. Immunosuppression, whether due to concurrent disease or medication, may increase susceptibility to bacterial invasion. Stress and dietary factors may exacerbate clinical signs but are not considered primary causes. Additionally, dogs with concurrent inflammatory bowel disease or other gastrointestinal disorders may be at increased risk. However, the exact role of these factors in the pathogenesis of HUC remains to be fully elucidated.

Clinical signs of histiocytic ulcerative colitis are primarily related to large-bowel diarrhea and include chronic or intermittent diarrhea, often with mucus and fresh blood (hematochezia). Affected dogs frequently exhibit tenesmus (straining to defecate), increased frequency of defecation, and urgency. The feces may be semi-formed to liquid, and the dog may pass small amounts frequently. Other signs include flatulence, borborygmus, and abdominal discomfort. In severe cases, weight loss, lethargy, and decreased appetite may be observed. Physical examination may reveal a normal body condition or mild emaciation, and abdominal palpation may elicit discomfort or reveal thickened bowel loops. Rectal examination may show mucosal irregularity, ulceration, or mass-like lesions. The disease is typically chronic and progressive if untreated, but clinical signs can wax and wane. In some cases, the disease may be mistaken for other causes of colitis, such as parasitic infections or dietary intolerance. The severity of clinical signs can vary, with some dogs showing mild intermittent signs and others having severe, debilitating diarrhea.

Differential diagnoses for histiocytic ulcerative colitis include other causes of chronic large-bowel diarrhea in dogs. Key differentials include: 1) Inflammatory bowel disease (lymphocytic-plasmacytic colitis) – distinguished by histopathology showing lymphocytic and plasmacytic infiltration, not histiocytic. 2) Eosinophilic colitis – characterized by eosinophilic infiltration, often associated with dietary or parasitic triggers. 3) Parasitic colitis (e.g., Trichuris vulpis, Giardia, Entamoeba) – identified via fecal examination and response to anthelmintics. 4) Bacterial colitis (e.g., Clostridium perfringens, Salmonella, Campylobacter) – diagnosed via fecal culture/PCR and response to appropriate antibiotics. 5) Fungal colitis (e.g., Histoplasma capsulatum, Pythium insidiosum) – more common in endemic areas, diagnosed via cytology, histopathology, or serology. 6) Colonic neoplasia (e.g., adenocarcinoma, lymphoma) – more common in older dogs, diagnosed via imaging and biopsy. 7) Irritable bowel syndrome – a functional disorder with no inflammatory changes on biopsy. 8) Dietary intolerance or allergy – diagnosed via dietary elimination trials. 9) Protein-losing enteropathy due to other causes – may present with similar clinical signs. Definitive diagnosis of HUC requires histopathological evaluation of colonic biopsies showing characteristic PAS-positive macrophages.

The diagnostic algorithm for histiocytic ulcerative colitis begins with a thorough history and physical examination, focusing on the chronicity and nature of diarrhea. The next step is to rule out common infectious and parasitic causes via fecal flotation, direct smear, and PCR for pathogens such as Giardia, Trichuris, and Salmonella. A complete blood count, serum biochemistry profile, and urinalysis are performed to assess overall health and rule out systemic disease. Fecal culture and antimicrobial susceptibility testing may be considered, but are not always diagnostic. Abdominal imaging, including radiography and ultrasonography, is useful to evaluate for thickening of the colonic wall and to rule out other gastrointestinal abnormalities. The gold standard for diagnosis is colonoscopy with mucosal biopsy. Endoscopic findings typically show diffuse erythema, erosions, ulcerations, and increased friability of the colonic mucosa. Histopathological examination of biopsy samples reveals the characteristic infiltration of the lamina propria by large, foamy macrophages that are PAS-positive. Immunohistochemistry may be used to confirm the presence of E. coli antigens within macrophages. In cases where colonoscopy is not feasible, exploratory laparotomy with full-thickness biopsy may be performed. Early and accurate diagnosis is crucial for successful treatment.

Laboratory findings in histiocytic ulcerative colitis are often non-specific. Complete blood count may reveal mild anemia due to chronic blood loss, and occasionally neutrophilia or eosinophilia. Serum biochemistry profile is usually within normal limits, but may show hypoalbuminemia in severe cases due to protein-losing enteropathy. Electrolyte imbalances, such as hypokalemia, may occur with chronic diarrhea. Fecal examination may reveal the presence of blood and mucus, but no specific pathogens are typically identified. Fecal culture may grow E. coli, but this is not diagnostic. In some cases, measurement of serum C-reactive protein (CRP) may show mild elevation, indicating systemic inflammation. Specific biomarkers for HUC are not available, but research has focused on identifying genetic markers or fecal microbiome changes. Histopathology remains the definitive diagnostic test, with PAS staining being essential to demonstrate the characteristic macrophages. Immunohistochemistry for E. coli antigens can support the diagnosis. Molecular techniques, such as PCR for E. coli genes, may be performed on biopsy samples to identify the presence of AIEC strains.

Imaging findings in histiocytic ulcerative colitis are generally non-specific but can support the diagnosis. Abdominal radiographs may show a normal or mildly thickened colonic wall, but are often unremarkable. Abdominal ultrasonography is more sensitive and may reveal thickening of the colonic wall, loss of normal layering, and increased echogenicity of the mucosa. In severe cases, the colon may appear as a hypoechoic, thickened structure. Color Doppler may show increased blood flow to the affected segment. Computed tomography (CT) is rarely used but can provide detailed images of the colon and may show wall thickening and contrast enhancement. Magnetic resonance imaging (MRI) is not commonly employed. Colonoscopy is the primary imaging modality for direct visualization of the mucosa, revealing erythema, erosions, ulcerations, and friability. Endoscopic findings are characteristic but not pathognomonic, and biopsy is required for confirmation. In some cases, the mucosa may appear nodular or have a cobblestone appearance. Fluoroscopy with barium enema may show mucosal irregularities but is rarely used in modern practice.

Cytology and histopathology are essential for the diagnosis of histiocytic ulcerative colitis. Fine needle aspiration of the colonic wall or rectal scraping may reveal large, foamy macrophages, but this is not commonly performed. The definitive diagnosis is made via histopathological examination of colonic biopsy samples. On histopathology, the lamina propria is diffusely infiltrated by large macrophages with abundant, foamy, eosinophilic cytoplasm. These macrophages are strongly positive for periodic acid-Schiff (PAS) stain, indicating the presence of intracellular glycoprotein or bacterial material. The inflammatory infiltrate may also include neutrophils, lymphocytes, and plasma cells, but the histiocytic component is predominant. The colonic mucosa shows ulceration, erosion, and crypt abscesses. There is often loss of goblet cells and architectural distortion of the crypts. In chronic cases, fibrosis may be present. Immunohistochemistry can be performed to demonstrate E. coli antigens within the macrophages, which is supportive of the diagnosis. Special stains, such as Gram stain, may also reveal gram-negative bacteria within macrophages. The histopathological findings are characteristic and allow differentiation from other forms of colitis.

The treatment of histiocytic ulcerative colitis has evolved significantly with the recognition of the role of E. coli. The current standard of care is antimicrobial therapy, particularly with fluoroquinolones, which have excellent intracellular penetration and activity against E. coli. The recommended protocol is enrofloxacin at a dosage of 5-10 mg/kg orally once daily for 8-10 weeks, or longer in some cases. Alternatively, ciprofloxacin at 10-15 mg/kg orally twice daily may be used. In addition to antimicrobials, supportive care is essential, including a highly digestible, low-residue diet, and possibly probiotics to restore normal gut flora. In severe cases, anti-inflammatory doses of corticosteroids (e.g., prednisone at 1-2 mg/kg/day) may be added initially to reduce inflammation, but they are not a substitute for antimicrobial therapy. In refractory cases, other immunomodulatory drugs such as azathioprine or cyclosporine may be considered, but their efficacy is not well established. Surgical intervention is rarely indicated, but in cases of stricture or perforation, resection may be necessary. Nutritional support is crucial, and in cases of protein-losing enteropathy, a high-protein diet may be recommended. Regular monitoring of clinical signs and fecal consistency is important to assess response to therapy. In most cases, antimicrobial therapy leads to significant improvement or remission, but relapse can occur, necessitating long-term management.

The prognosis for histiocytic ulcerative colitis is generally good with appropriate antimicrobial therapy. Most dogs show significant improvement within 2-4 weeks of starting enrofloxacin, and many achieve complete remission. The long-term prognosis is favorable, with many dogs remaining in remission for months to years. However, relapse can occur, and some dogs may require prolonged or repeated courses of antibiotics. The prognosis is worse in cases with severe ulceration, fibrosis, or concurrent diseases. Early diagnosis and treatment are associated with a better outcome. In untreated cases, the disease is progressive and can be fatal due to severe debilitation, protein-losing enteropathy, or secondary infections. The overall mortality rate is low with appropriate treatment. Factors that negatively affect prognosis include delayed diagnosis, poor response to initial therapy, and the development of complications such as stricture or perforation. Regular follow-up and monitoring are essential to detect relapse early and adjust treatment accordingly.

Follow-up for histiocytic ulcerative colitis involves regular re-evaluation of clinical signs and fecal consistency. After initiating antimicrobial therapy, a re-check should be performed within 2-4 weeks to assess response. If there is improvement, the antibiotic course should be completed (typically 8-10 weeks). After completion of therapy, dogs should be monitored for recurrence of signs. A re-check examination, including fecal analysis and possibly blood work, is recommended at 3-6 months post-treatment. In cases of relapse, a repeat course of antibiotics may be necessary, and in some cases, long-term low-dose maintenance therapy may be considered. Serial colonoscopy with biopsy may be performed to confirm histological remission, but this is not routinely necessary. Monitoring for potential side effects of antibiotics, such as cartilage damage in young dogs (enrofloxacin), is important. Owners should be educated on the importance of dietary management and avoiding potential triggers. Long-term follow-up should include regular veterinary visits every 6-12 months to monitor for disease recurrence and overall health.

Clinical Pearls: 1) Histiocytic ulcerative colitis should be suspected in any young Boxer dog with chronic large-bowel diarrhea, especially if there is hematochezia and tenesmus. 2) Early colonoscopy with biopsy is crucial for diagnosis; PAS staining is essential to identify the characteristic macrophages. 3) Enrofloxacin is the treatment of choice, and a positive response to therapy supports the diagnosis. 4) The disease is often misdiagnosed as lymphocytic-plasmacytic colitis; histopathology is key to differentiation. 5) In refractory cases, consider the possibility of concurrent infections or antibiotic resistance. Clinical Pitfalls: 1) Failure to perform colonoscopy and biopsy can lead to misdiagnosis and inappropriate treatment with corticosteroids alone, which may worsen the condition. 2) Using corticosteroids as the sole therapy without antimicrobials is ineffective and may allow progression of the disease. 3) Underdosing or shortening the duration of enrofloxacin can lead to relapse. 4) Not considering other causes of colitis, such as parasites or dietary intolerance, can delay appropriate treatment. 5) Overlooking the potential for enrofloxacin-induced cartilage damage in young, growing dogs; alternative antibiotics may be considered in puppies.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for histiocytic ulcerative colitis: 1) Enrofloxacin (Baytril): Dosage: 5-10 mg/kg orally once daily (or divided twice daily) for 8-10 weeks. In severe cases, initial parenteral administration (5 mg/kg IV or SC once daily) may be used. Caution in young dogs due to potential cartilage arthropathy; use alternative if <8 months of age. 2) Ciprofloxacin: 10-15 mg/kg orally twice daily for 8-10 weeks as an alternative. 3) Metronidazole: 10-15 mg/kg orally twice daily may be added for its anaerobic coverage and immunomodulatory effects, but is not a primary treatment. 4) Prednisone: 1-2 mg/kg orally once daily, tapering over 2-4 weeks, may be used initially to reduce inflammation, but should not be used alone. 5) Sulfasalazine: 20-30 mg/kg orally three times daily (max 3 g/day) may be considered for its anti-inflammatory effects on the colon, but is not effective against intracellular E. coli. 6) Azathioprine: 2 mg/kg orally once daily (max 50 mg/dog) may be used in refractory cases, but has a slow onset of action (3-6 weeks). 7) Cyclosporine: 5-10 mg/kg orally once daily may be considered for severe refractory cases, but requires monitoring of blood levels. 8) Probiotics (e.g., FortiFlora) and prebiotics may be used as adjunctive therapy to restore gut flora. 9) Dietary management with a highly digestible, low-residue diet is essential. 10) In cases of protein-losing enteropathy, consider parenteral nutrition or high-protein diet. All dosages should be adjusted based on renal and hepatic function, and drug interactions should be considered, especially with fluoroquinolones and antacids.

The understanding of histiocytic ulcerative colitis has been advanced by several key studies. A landmark study by Simpson et al. (2006) identified adherent and invasive E. coli in the colonic mucosa of Boxer dogs with HUC, and demonstrated that enrofloxacin treatment led to clinical and histological remission. This study established the infectious etiology and the rationale for antimicrobial therapy. Subsequent research by Craven et al. (2011) further characterized the AIEC strains and their genetic features. A study by Manchester et al. (2013) evaluated the long-term outcome of HUC in Boxer dogs treated with enrofloxacin, showing a high rate of remission but also a risk of relapse. Consensus guidelines from the ACVIM (2010) on canine chronic inflammatory enteropathies recommend histopathology for diagnosis and antimicrobial therapy for granulomatous colitis. More recent studies have explored the role of the microbiome and potential genetic markers. A study by Rossi et al. (2014) investigated the fecal microbiome in HUC and found dysbiosis. Research is ongoing to identify specific genetic mutations associated with the disease. Overall, the evidence supports the use of fluoroquinolones as the first-line treatment, with a good prognosis if diagnosed early.